Melissa Fanton
Physician Assistant · Springville, NYNPI 1902998974
Payments from drug & device makers
Across 276 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$667
- Lilly USA, LLC$622
- AbbVie$538
- GSK$382
- Gilead$350
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,099100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $1,430 |
| Novo Nordisk | 40 | $667 |
| Lilly USA, LLC | 40 | $622 |
| AbbVie | 26 | $538 |
| GSK | 27 | $382 |
| Gilead | 12 | $350 |
| Amgen | 11 | $185 |
| Exact Sciences | 9 | $180 |
| Pfizer | 10 | $177 |
| Merck | 9 | $169 |
| Phathom Pharmaceuticals, Inc. | 6 | $148 |
| Edwards Lifesciences | 6 | $132 |
| Abbott | 6 | $117 |
| Astellas Pharma US Inc | 5 | $104 |
| Bayer | 5 | $102 |
| Axsome Therapeutics, Inc. | 1 | $88 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $75 |
| Dexcom, Inc. | 4 | $64 |
| Sanofi-aventis U.S. LLC | 4 | $57 |
| Alk-abello, Inc | 3 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $51 |
| Boehringer Ingelheim | 2 | $51 |
| Lundbeck LLC | 3 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Vertex | 1 | $26 |
| Advanced Oxygen Therapy Inc. | 2 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Cipher Pharmaceuticals US LLC | 1 | $20 |
| Insulet Corporation | 1 | $19 |
| Novartis | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,099 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 172 | $212,081 |
| EliquisApixaban | 143 | $151,436 |
| JardianceEmpagliflozin | 120 | $95,099 |
| FarxigaDapagliflozin Propanediol | 75 | $62,810 |
| TrulicityDulaglutide | 42 | $53,543 |
| XifaxanRifaximin | 14 | $53,099 |
| MounjaroTirzepatide | 47 | $50,502 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $44,748 |
| XareltoRivaroxaban | 42 | $35,033 |
| MyrbetriqMirabegron | 50 | $34,139 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $23,165 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $20,612 |
| EntrestoSacubitril/Valsartan | 14 | $17,689 |
| JanuviaSitagliptin Phosphate | 13 | $14,071 |
| TrintellixVortioxetine Hydrobromide | 23 | $10,650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $667 | $212,081172 claims |
| PfizerEliquis, Lyrica | $177 | $158,740156 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $622 | $104,04589 claims |
| Boehringer IngelheimJardiance | $51 | $95,099120 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $1,430 | $88,287115 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $75 | $53,09914 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $382 | $49,92365 claims |
| Astellas Pharma US IncMyrbetriq | $104 | $34,13950 claims |
| NovartisEntresto | $17 | $17,68914 claims |
| MerckJanuvia | $169 | $14,07113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Springville
- Henry YuBronx$1M
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
- Lawrence HermanHolbrook$315K
- Kaitlyn NelsonBrooklyn$289K
- Sari KatzGarden City$271K
- Julius NwosuBronx$256K
- Cameron KiserNew York$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.